Skip to main content

Table 2 Disease response per RECIST v1.1

From: Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study

 

TGC (n = 14)

GC (n = 17)

p value

Best overall response, n (%)

Objective response rate, % (95% CI)

57.1 (27, 87)

47.1 (21, 74)

0.59

Complete response

2 (14.3)

2 (11.8)

 

Partial response

6 (42.9)

6 (35.3)

 

Stable disease

5 (35.7)

5 (29.4)

 

Progressive disease

1 (7.1)

2 (11.8)

 

Missing or unevaluable

0 (0)

2 (11.8)

 

Disease control rate, % (95% CI)

71.4 (44, 98)

64.7 (39, 90)

0.96

Clinical benefit rate, % (95% CI)

64.3 (36, 93)

52.9 (26, 79)

0.54

  1. RECIST v1.1 Response evaluation criteria in solid tumors version 1.1, TGC tislelizumab plus gemcitabine and cisplatin, GC gemcitabine and cisplatin, CI confidence interval
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us